公开(公告)号：US20200368204A1

公开(公告)日：2020-11-26

申请号：US16986863

申请日：2020-08-06

申请人： King Abdulaziz University

发明人： Moustafa E. EL-ARABY ,  Abdelsattar Mansour Omar ,  Mahmoud Abdelkhalek El-Faky ,  Sameh Hamdy Abdelmageed Soror ,  Maan Talaat Khayat ,  Hani Zakariah Asfour ,  Faida Hassan Bamane

IPC分类号： A61K31/4164 ,  A61P31/14

摘要： Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.

公开(公告)号：US10821096B1

公开(公告)日：2020-11-03

申请号：US16986863

申请日：2020-08-06

申请人： King Abdulaziz University

发明人： Moustafa E. El-Araby ,  Abdelsattar Mansour Omar ,  Mahmoud Abdelkhalek El-Faky ,  Sameh Hamdy Abdelmageed Soror ,  Maan Talaat Khayat ,  Hani Zakariah Asfour ,  Faida Hassan Bamane

IPC分类号： A61K31/4164 ,  A61K31/55 ,  C07D233/64 ,  C07D233/54 ,  C07C279/04 ,  C07C279/10 ,  C07C279/12 ,  C07D279/16 ,  A61P31/14

摘要： Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.

公开(公告)号：US10959987B2

公开(公告)日：2021-03-30

申请号：US16384472

申请日：2019-04-15

申请人： King Abdulaziz University

发明人： Moustafa E. El-Araby ,  Abdelsattar Mansour Omar ,  Mahmoud Abdelkhalek El-Faky ,  Sameh Hamdy Abdelmageed Soror ,  Maan Talaat Khayat ,  Hani Zakariah Asfour ,  Faida Hassan Bamane

IPC分类号： A61K31/4164 ,  A61K31/55 ,  C07D233/64 ,  C07D233/54 ,  C07C279/04 ,  C07C279/10 ,  C07C279/12 ,  C07C279/16 ,  A61P31/14

摘要： Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.

公开(公告)号：US20200369727A1

公开(公告)日：2020-11-26

申请号：US16986706

申请日：2020-08-06

申请人： King Abdulaziz University

发明人： Moustafa E. EL-ARABY ,  Abdelsattar Mansour Omar ,  Mahmoud Abdelkhalek El-Faky ,  Sameh Hamdy Abdelmageed Soror ,  Maan Talaat Khayat ,  Hani Zakariah Asfour ,  Faida Hassan Bamane

IPC分类号： C07K7/08 ,  G01N33/576 ,  A61K45/06 ,  A61K38/10 ,  A61P31/14

摘要： Peptide inhibitors of activation of hepatitis C virus (HCV) NS3 protease are disclosed. They are analogs of the activation peptide HCV NS4 of residues 21-33 of SEQ ID NO: 2 and contain non-proteinogenic amino acids. Competitive binding studies showed the peptide analogs bind HCV NS3 protease at the activation site.

公开(公告)号：US20200323822A1

公开(公告)日：2020-10-15

申请号：US16384472

申请日：2019-04-15

申请人： King Abdulaziz University

发明人： Moustafa E. EL-ARABY ,  Abdelsattar Mansour Omar ,  Mahmoud Abdelkhalek El-Faky ,  Sameh Hamdy Abdelmageed Soror ,  Maan Talaat Khayat ,  Hani Zakariah Asfour ,  Faida Bamane

IPC分类号： A61K31/4164 ,  A61P31/14

摘要： Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.